<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383942</url>
  </required_header>
  <id_info>
    <org_study_id>109040</org_study_id>
    <nct_id>NCT00383942</nct_id>
  </id_info>
  <brief_title>Ripening Interventions: Prostaglandins vs EASI Catheter</brief_title>
  <acronym>RIPE</acronym>
  <official_title>The RIPE Study: Ripening Interventions: Prostaglandins vs EASI Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this randomized clinical trial is to compare the effect of misoprostol vs
      extra amniotic saline infusion via a catheter (EASI) for cervical ripening on the proportion
      of patients delivered by cesarean section for fetal intolerance of labor versus vaginal
      delivery. The primary hypothesis is that patients undergoing cervical ripening with EASI
      catheter are less likely to undergo cesarean section for fetal intolerance of labor when
      compared to women who receive misoprostol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of labor is a common obstetrical practice. In fact, the rate of induction has risen
      to 184/1000 live births. It is well known that a favorable Bishop score, defined as Bishop
      score 5-8, improves the safety and success rate for induction of labor and vaginal delivery.
      Several methods for cervical ripening, both mechanical and pharmacological, have been
      developed to improve Bishop score in women eligible for induction of labor with an
      unfavorable cervix. These methods include: misoprostol, dinoprostone, intracervical catheter
      with and without extra-amniotic saline infusion, and laminaria.

      Several studies have investigated the optimum cervical ripening agent, and review of current
      literature supports that misoprostol given in a dose of 25 micrograms every 4 hours
      intravaginally as the most efficacious and inexpensive regimen while maintaining safe
      maternal and fetal outcomes. Several studies have shown that misoprostol has a significantly
      shorter time to delivery compared with other methods of ripening. In fact, in a 2003 Cochrane
      Database Systematic Review, misoprostol was shown to have increased cervical ripening
      effectiveness and reduced failure to achieve vaginal delivery in 12-24 hours. Further, while
      uterine hyper-stimulation and tachysystole were more common in the misoprostol groups, no
      adverse neonatal outcomes were described. However, misoprostol has been shown to have a
      higher incidence of cesarean section for fetal intolerance to labor compared to other
      cervical ripening methods including EASI. Several studies support the ideal route of
      administration and dosage of misoprostol to be 25 micrograms every 4 hours intravaginally.
      This regimen leads to effective cervical ripening while reducing the dose-dependent effect of
      misoprostol on uterine tachysystole and hyperstimulation. Another aspect to consider in
      cervical ripening method is cost. Misoprostol is much less expensive than other methods
      including dinoprostone. In fact, one article reports that the average cost per patient for
      misoprostol treatment was $85 compared to $606 for dinoprostone insert.

      Extra-amniotic saline infusion (EASI) has been introduced as a mechanical,
      non-pharmacological cervical ripening method. It involves placement of a Foley catheter
      through the cervix and is supplemented with continuous extra-amniotic infusion of saline.
      This is thought to improve prostaglandin release, resulting in shortened duration of labor.
      Several studies have been performed to determine the safety and efficacy of the EASI method.

      Since misoprostol is efficacious, safe, and inexpensive, it is a superior method for cervical
      ripening and will act as a control for an experimental group undergoing cervical ripening
      with the EASI catheter. Our hypothesis is that cervical ripening with the EASI method will
      result in fewer cesarean sections for fetal intolerance to labor as compared to misoprostol.
      Furthermore, patients undergoing cervical ripening with EASI will experience a shorter time
      to delivery, have less expense, have fewer adverse effects, and will be more satisfied with
      EASI catheter than with misoprostol.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in treatment plan for this population terminated the project
  </why_stopped>
  <start_date type="Actual">August 31, 2006</start_date>
  <completion_date type="Actual">June 18, 2008</completion_date>
  <primary_completion_date type="Actual">June 18, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Women Undergoing Cesarean Section for Fetal Intolerance of Labor</measure>
    <time_frame>At time of delivery</time_frame>
    <description>The number of women undergoing cesarean section will be compared between the misoprostol arm and EASI arm. The primary hypothesis is that the odds of receiving a cesarean section is lower among patients assigned to EASI when compared to patients who receive misoprostol.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EASI Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Misoprostol,25 micrograms every 4 hours.</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter</intervention_name>
    <description>A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen</description>
    <arm_group_label>EASI Catheter</arm_group_label>
    <other_name>EASI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy

          -  Cephalic presentation

          -  36 completed weeks of gestation

          -  Intact membranes

          -  Unfavorable cervix (defined as Bishop score &lt; 5)

          -  Indication for induction of labor

          -  Fetal Station less than or equal to -3

        Exclusion Criteria:

          -  Clinically significant vaginal bleeding

          -  Evidence of spontaneous labor (3 contractions in 10 minutes)

          -  Contraindication to induction of labor or to use of prostaglandins

          -  Fetal station higher than -3
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Graziano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson DP, Davis NR, Brown AJ. Risk of cesarean delivery after induction at term in nulliparous women with an unfavorable cervix. Am J Obstet Gynecol. 2003 Jun;188(6):1565-9; discussion 1569-72.</citation>
    <PMID>12824994</PMID>
  </reference>
  <reference>
    <citation>Afolabi BB, Oyeneyin OL, Ogedengbe OK. Intravaginal misoprostol versus Foley catheter for cervical ripening and induction of labor. Int J Gynaecol Obstet. 2005 Jun;89(3):263-7. Epub 2005 Apr 2.</citation>
    <PMID>15919393</PMID>
  </reference>
  <reference>
    <citation>Karjane NW, Brock EL, Walsh SW. Induction of labor using a foley balloon, with and without extra-amniotic saline infusion. Obstet Gynecol. 2006 Feb;107(2 Pt 1):234-9.</citation>
    <PMID>16449106</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Ramos L, Peterson DE, Delke I, Gaudier FL, Kaunitz AM. Labor induction with prostaglandin E1 misoprostol compared with dinoprostone vaginal insert: a randomized trial. Obstet Gynecol. 1998 Mar;91(3):401-5.</citation>
    <PMID>9491868</PMID>
  </reference>
  <reference>
    <citation>Garry D, Figueroa R, Kalish RB, Catalano CJ, Maulik D. Randomized controlled trial of vaginal misoprostol versus dinoprostone vaginal insert for labor induction. J Matern Fetal Neonatal Med. 2003 Apr;13(4):254-9.</citation>
    <PMID>12854927</PMID>
  </reference>
  <reference>
    <citation>Adeniji OA, Oladokun A, Olayemi O, Adeniji OI, Odukogbe AA, Ogunbode O, Aimakhu CO, Omigbodun AO, Ilesanmi AO. Pre-induction cervical ripening: transcervical foley catheter versus intravaginal misoprostol. J Obstet Gynaecol. 2005 Feb;25(2):134-9.</citation>
    <PMID>15814391</PMID>
  </reference>
  <reference>
    <citation>Abramovici D, Goldwasser S, Mabie BC, Mercer BM, Goldwasser R, Sibai BM. A randomized comparison of oral misoprostol versus Foley catheter and oxytocin for induction of labor at term. Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1108-12.</citation>
    <PMID>10561627</PMID>
  </reference>
  <reference>
    <citation>Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD000941. doi: 10.1002/14651858.CD000941.pub2. Review.</citation>
    <PMID>20927722</PMID>
  </reference>
  <reference>
    <citation>le Roux PA, Olarogun JO, Penny J, Anthony J. Oral and vaginal misoprostol compared with dinoprostone for induction of labor: a randomized controlled trial. Obstet Gynecol. 2002 Feb;99(2):201-5.</citation>
    <PMID>11814497</PMID>
  </reference>
  <reference>
    <citation>Guinn DA, Goepfert AR, Christine M, Owen J, Hauth JC. Extra-amniotic saline, laminaria, or prostaglandin E(2) gel for labor induction with unfavorable cervix: a randomized controlled trial. Obstet Gynecol. 2000 Jul;96(1):106-12.</citation>
    <PMID>10862852</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Ramos L, Kaunitz AM, Wears RL, Delke I, Gaudier FL. Misoprostol for cervical ripening and labor induction: a meta-analysis. Obstet Gynecol. 1997 Apr;89(4):633-42.</citation>
    <PMID>9083326</PMID>
  </reference>
  <reference>
    <citation>Meydanli MM, Calişkan E, Burak F, Narin MA, Atmaca R. Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol. Int J Gynaecol Obstet. 2003 Jun;81(3):249-55.</citation>
    <PMID>12767565</PMID>
  </reference>
  <reference>
    <citation>Has R, Batukan C, Ermis H, Cevher E, Araman A, Kiliç G, Ibrahimoğlu L. Comparison of 25 and 50 microg vaginally administered misoprostol for preinduction of cervical ripening and labor induction. Gynecol Obstet Invest. 2002;53(1):16-21.</citation>
    <PMID>11803223</PMID>
  </reference>
  <reference>
    <citation>Diro M, Adra A, Gilles JM, Nassar A, Rodriguez A, Salamat SM, Beydoun SN, O'Sullivan MJ, Yasin SY, Burkett G. A double-blind randomized trial of two dose regimens of misoprostol for cervical ripening and labor induction. J Matern Fetal Med. 1999 May-Jun;8(3):114-8.</citation>
    <PMID>10338065</PMID>
  </reference>
  <reference>
    <citation>Sharami SH, Milani F, Zahiri Z, Mansour-Ghanaei F. A randomized trial of prostaglandin E2 gel and extra-amniotic saline infusion with high dose oxytocin for cervical ripening. Med Sci Monit. 2005 Aug;11(8):CR381-6. Epub 2005 Jul 25.</citation>
    <PMID>16049380</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2006</study_first_posted>
  <results_first_submitted>June 1, 2016</results_first_submitted>
  <results_first_submitted_qc>January 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2017</results_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Scott Graziano</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Extra amniotic saline infusion</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Labor induction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for the trial opened at Loyola University Medical Center (Maywood, IL) on 08/31/2006 and closed on 06/05/2008.</recruitment_details>
      <pre_assignment_details>There are no pre-assignment details</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol</title>
          <description>Patients randomized to this arm receive 25 micrograms of misoprostol every 4 hours.</description>
        </group>
        <group group_id="P2">
          <title>EASI</title>
          <description>Patients randomized to this arm receive an extra amniotic saline infusion via catheter that is placed in the uterus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population comprises all patients who were randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol</title>
          <description>Patients randomized to this arm receive 25 micrograms of misoprostol every 4 hours.</description>
        </group>
        <group group_id="B2">
          <title>EASI</title>
          <description>Patients randomized to this arm receive extra amniotic saline infusion via a catheter that is placed in the uterus</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Women Undergoing Cesarean Section for Fetal Intolerance of Labor</title>
        <description>The number of women undergoing cesarean section will be compared between the misoprostol arm and EASI arm. The primary hypothesis is that the odds of receiving a cesarean section is lower among patients assigned to EASI when compared to patients who receive misoprostol.</description>
        <time_frame>At time of delivery</time_frame>
        <population>No participants are included in this analysis because the trial was terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Patients randomized to this arm receive 25 micrograms of misoprostol every 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>EASI</title>
            <description>Patients randomized to this arm recieve extra amniotic saline infusion (EASI) via a catheter that is placed in the uterus</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Women Undergoing Cesarean Section for Fetal Intolerance of Labor</title>
          <description>The number of women undergoing cesarean section will be compared between the misoprostol arm and EASI arm. The primary hypothesis is that the odds of receiving a cesarean section is lower among patients assigned to EASI when compared to patients who receive misoprostol.</description>
          <population>No participants are included in this analysis because the trial was terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 1 year, 9 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol</title>
          <description>Patients assigned to this arm received 25 micrograms of misoprostol every 4 hours</description>
        </group>
        <group group_id="E2">
          <title>EASI</title>
          <description>Patients assigned to this arm received extra amniotic saline infusion via a catheter that is placed in the uterus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was terminated prematurely due to a department policy change regarding inductions of labor.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Scott Graziano, M.D.</name_or_title>
      <organization>Loyola University</organization>
      <phone>708-216-6288</phone>
      <email>sgrazia@lumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

